Opioids

Law
McKinsey set to pay $550 million in opioid dispute
McKinsey set to pay $550 million in opioid dispute
Credit: unsplash.com / Hal Gatewood

Because of its role in the opioid crisis, McKinsey has agreed to a settlement of at least $550 million to resolve lawsuits. This was reported by the "New York Times" with reference to insiders.

McKinsey had advised OxyContin maker Purdue Pharma and its owning Sackler family. Purdue is accused of using predatory methods to push the prescribing of its drugs. The company filed for bankruptcy in 2019 as part of a proposed ten billion dollar settlement.

More than 40 US states had sued the consulting firm over McKinsey's role in the opioid crisis. The settlement was joined by 43 states, the Washington D.C. District and three United States territories, insiders report. Several state attorneys general announced a memo on the opioid epidemic for Thursday.

Health
Research: Legal cannabis stores linked to fewer opioid deaths in the United States
Research: Legal cannabis stores linked to fewer opioid deaths in the United States
Credit: unsplash.com / Alex Person

Access to legal cannabis stores is associated with a reduction in opioid-related deaths in the United States, particularly those linked to synthetic opioids such as fentanyl, finds a study published by The BMJ.

It is estimated that an increase from one to two cannabis dispensaries in a county was associated with an estimated 17% reduction in all opioid-related mortality rates. An increase from two to three dispensaries was associated with a further 8.5% reduction in all opioid related mortality rates. Their findings are based on data for 812 counties within the 23 US states that allowed legal cannabis dispensaries to operate by the end of 2017.